Updated Jun 16, 3:14 AM · 60 sources analyzed
Key Takeaways
Lilly's AJ1-11095 showed early myelofibrosis activity at EHA, validating the Ajax acquisition and signaling a potential Jakafi challenger.
Roche's tiragolumab Phase 3 NSCLC termination adds to mounting evidence that anti-TIGIT combinations face a steep clinical hurdle.
Medicare's new GLP-1 bridge program is structurally hard to end, likely creating durable demand that expands Lilly and Novo Nordisk's market.
🏆 Winner
Eli Lilly — early Phase 1 myelofibrosis data for AJ1-11095 supports Ajax deal value and opens a new oncology franchise.
📉 Loser
Roche — tiragolumab Phase 3 termination in NSCLC continues a series of failures for its anti-TIGIT program.
🔭 Watch Next
Full efficacy data from Lilly's AJ1-11095 Phase 1 study, expected to be presented or published in greater detail following the EHA 2026 conference, will determine whether advancement to a registrational trial is warranted.
Lilly's Ajax-acquired JAK2 drug shows early myelofibrosis signal
Eli Lilly presented Phase 1 results for AJ1-11095, a type II JAK2 inhibitor acquired through its purchase of biotech startup Ajax, at the European Hematology Association annual meeting in Stockholm. The drug showed encouraging efficacy signals in patients with hard-to-treat myelofibrosis, though specific figures were not disclosed in available reports. If the signal holds in larger studies, AJ1-11095 could emerge as a competitor to Incyte's Jakafi, the current standard of care in myelofibrosis.
MedCity News ↗Hoffmann-La Roche
Tiragolumab + atezolizumab in Resected non-small cell lung cancer (NSCLC) post adjuvant chemotherapy
Specific figures not disclosed. The Phase 3 study (NCT06267001) evaluating tiragolumab plus atezolizumab versus placebo plus atezolizumab in completely resected NSCLC patients was terminated.
Why it matters
Another termination for the tiragolumab program deepens concerns about the anti-TIGIT class's clinical utility and strengthens the position of existing adjuvant checkpoint inhibitor regimens in early NSCLC.
National Cancer Institute (NCI) / Regeneron Pharmaceuticals
Cemiplimab (REGN2810) in Advanced skin squamous cell carcinoma (eyelid and acantholytic subtypes)
Specific figures not disclosed. Phase 3 trial (NCT06568172) testing cemiplimab added to surgery in advanced skin cancer is currently suspended.
Why it matters
Suspension of this NCI-sponsored trial delays potential label expansion for cemiplimab in rare, hard-to-treat skin cancer subtypes and leaves a treatment gap for patients with limited surgical options.
Regeneron Pharmaceuticals
CMP-001 + nivolumab in Advanced melanoma
Specific figures not disclosed. The Phase 2/3 study (NCT04695977) of intratumoral CMP-001 plus intravenous nivolumab versus nivolumab monotherapy was terminated.
Why it matters
Termination of this combination immunotherapy study in melanoma narrows the competitive field for intratumoral TLR9 agonist approaches and removes a potential challenge to established checkpoint inhibitor monotherapy regimens.
Eli Lilly
AJ1-11095 in Myelofibrosis
Specific figures not disclosed. Phase 1 data presented at EHA 2026 described as showing encouraging efficacy signals in hard-to-treat myelofibrosis patients.
Why it matters
A validated Phase 1 signal for a next-generation type II JAK2 inhibitor positions Lilly as a credible challenger to Incyte's Jakafi franchise and validates the Ajax acquisition.
Specific figures not disclosed. Phase 1 data presented at EHA 2026 described as showing encouraging efficacy signals in hard-to-treat myelofibrosis patients.
Why it matters
A validated Phase 1 signal for a next-generation type II JAK2 inhibitor positions Lilly as a credible challenger to Incyte's Jakafi franchise and validates the Ajax acquisition.
Specific figures not disclosed. The Phase 2/3 study (NCT04695977) of intratumoral CMP-001 plus intravenous nivolumab versus nivolumab monotherapy was terminated.
Why it matters
Termination of this combination immunotherapy study in melanoma narrows the competitive field for intratumoral TLR9 agonist approaches and removes a potential challenge to established checkpoint inhibitor monotherapy regimens.
Specific figures not disclosed. The Phase 3 study (NCT06267001) evaluating tiragolumab plus atezolizumab versus placebo plus atezolizumab in completely resected NSCLC patients was terminated.
Why it matters
Another termination for the tiragolumab program deepens concerns about the anti-TIGIT class's clinical utility and strengthens the position of existing adjuvant checkpoint inhibitor regimens in early NSCLC.
Specific figures not disclosed. Phase 3 trial (NCT06568172) testing cemiplimab added to surgery in advanced skin cancer is currently suspended.
Why it matters
Suspension of this NCI-sponsored trial delays potential label expansion for cemiplimab in rare, hard-to-treat skin cancer subtypes and leaves a treatment gap for patients with limited surgical options.
Specific figures not disclosed. Phase 3 study (NCT04607421) is active but no longer recruiting; results are pending.
Why it matters
Enrollment completion moves this BRAF-targeted combination closer to a potential readout that could reshape first-line treatment for BRAF-mutant metastatic colorectal cancer, a segment with few approved options.
FDA approved Colorado's plan to import certain prescription drugs from Canada, making it the second U.S. state to receive such authorization.
Why it matters
A second state-level import approval increases pressure on branded drug manufacturers to lower list prices and signals that drug importation is becoming an established policy tool rather than a theoretical threat.
A temporary Medicare GLP-1 bridge program for adults 65 and older will make obesity drugs available to Medicare beneficiaries for the first time starting next month, though the program is structured as temporary.
Why it matters
Because Medicare is legally barred from covering weight-loss drugs long-term without congressional action, a program that proves difficult to terminate could create durable demand for GLP-1 therapies and significantly expand the addressable market for Novo Nordisk and Eli Lilly.
Lipid nanoparticle stereochemistry alters mRNA delivery efficiency
A preprint on bioRxiv reports that the stereochemical arrangement (three-dimensional molecular shape) of lipids inside nanoparticles substantially changes how well mRNA is expressed inside cells, affecting pharmacokinetics and efficacy.
Why it matters
Optimizing lipid chirality (mirror-image molecular structure) in nanoparticle formulations could become a key lever for improving next-generation mRNA therapeutics and vaccines without changing the genetic payload.
iRhom2 adapter protein drives acute lung inflammation via ADAM17
A bioRxiv preprint shows that iRhom2, a non-enzymatic adapter protein predominantly expressed in immune cells, is required for ADAM17 to shed inflammatory molecules including TNF and IL-6R during acute lung injury.
Why it matters
Selective targeting of iRhom2 rather than ADAM17 itself could reduce lung inflammation with fewer off-target effects, offering a more specific approach to conditions such as acute respiratory distress syndrome (ARDS).
Dual-action hERG blocker simultaneously opens cardiac potassium channels
A bioRxiv preprint describes a drug compound that blocks hERG potassium channels (associated with dangerous heart rhythm disturbances) while paradoxically also facilitating channel opening, revealing a previously unknown agonist-blocker dual mechanism.
Why it matters
Understanding this dual mechanism could help medicinal chemists design drugs that retain therapeutic potency while reducing the cardiac arrhythmia risk that causes many drug candidates to fail safety screening.
Pfizer
Pfizer's Bicillin (injectable penicillin) shortage has worsened, with an Arizona pregnant woman unable to receive timely syphilis treatment, resulting in a preventable congenital syphilis diagnosis in her newborn.
Why it matters
The case illustrates direct patient harm from drug supply chain failures and is likely to intensify regulatory and congressional scrutiny of Pfizer's manufacturing obligations for essential antibiotics.
Oral GLP-1 competing directly with Lilly and Novo. Best-in-class efficacy in Phase 2 at ~15% weight loss. Phase 3 success could make Viking an M&A target.
Lilly presented Phase 1 data for AJ1-11095, a type II JAK2 inhibitor acquired via the Ajax deal, at EHA 2026, showing encouraging signals in myelofibrosis. The Ajax acquisition appears strategically justified based on early clinical data.
MedCity News ↗A new temporary Medicare GLP-1 bridge program will provide obesity drug coverage to adults 65 and older starting next month; structural features of the program could make it difficult to terminate, potentially expanding the GLP-1 addressable market.
STAT News ↗Pfizer's Bicillin (injectable penicillin) shortage has caused a preventable congenital syphilis case in Arizona, drawing renewed public and regulatory attention to the company's emergency penicillin access program and its supply chain management.
STAT News ↗Two Regeneron-linked trials were updated on ClinicalTrials.gov: the CMP-001 plus nivolumab melanoma study was terminated, and the NCI-sponsored cemiplimab skin cancer Phase 3 trial is suspended.
ClinicalTrials.gov ↗Two AstraZeneca Phase 3 trials are active but no longer recruiting: a durvalumab plus bevacizumab/olaparib study in advanced ovarian cancer, and a trastuzumab deruxtecan (T-DXd) study in HER2-positive early breast cancer, both awaiting results.
ClinicalTrials.gov ↗Roche's Phase 3 trial of tiragolumab plus atezolizumab in resected NSCLC patients was terminated, adding to a pattern of setbacks for the tiragolumab anti-TIGIT program.
ClinicalTrials.gov ↗A Phase 2 biomarker-directed pembrolizumab combination study in advanced NSCLC (KEYNOTE-495, NCT03516981) was marked as completed on ClinicalTrials.gov; results have not been separately disclosed in today's sources.
ClinicalTrials.gov ↗